Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505923-30-00

Acronym

CSET N° 2020/3188

Enrollment

139

Registered

2024-08-21

Start date

2021-05-11

Completion date

Unknown

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

including only one line of chemotherapy for advanced/metastatic disease., Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France

Outcome results